{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-297658","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2026-07-07T21:24:32+00:00","discovered_at":"2026-07-07T21:26:00.297458+00:00","generated_at":"2026-07-07T21:26:04.267659+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ResMed sells MatrixCare to Frazier Healthcare for $490M cash; sharpens focus on sleep health","bullets":["All-cash deal valued at $490M, subject to closing adjustments; expected to close in Q1 FY2027.","MatrixCare had ~$220M revenue and ~$55M non-GAAP operating profit in FY2026.","Net proceeds to be used for share repurchases (ASR) and general corporate purposes.","Noctrix acquisition expected to add ~$30M revenue but reduce non-GAAP diluted EPS by ~$0.20 in FY2027.","ResMed reiterates FY2026 non-GAAP margin, SG&A, R&D, and tax rate outlook; full FY2027 guidance on Aug 6 call."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-297658","json":"https://secwatch.observer/filing/0001193125-26-297658.json","markdown":"https://secwatch.observer/filing/0001193125-26-297658.md","text":"https://secwatch.observer/filing/0001193125-26-297658.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/0001193125-26-297658-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312526297658/d88958d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T21:26:04.267659+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}